Newsroom

Takeda Corporate Information

To learn about our parent company, Takeda Pharmaceutical Company Limited, please visit http://www.takeda.com/

Media Inquiries

For media inquiries or reporter requests for more information, contact our Corporate Communications via Media_Relations@takeda.com. If you generally would like to contact us, please visit Contact Us.

Recent News Releases

June 22, 2022 6/22/2022

Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts

April 18, 2022 4/18/2022

Takeda’s TAKHZYRO^® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States

February 9, 2022 2/9/2022

Takeda Receives U.S. FDA Approval for Prefilled Syringe Presentation of TAKHZYRO^® (lanadelumab-flyo) for Use as a Preventive Treatment for Hereditary Angioedema Attacks

January 31, 2022 1/31/2022

FDA Approves Prophylactic Treatment with VONVENDI^® [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)

December 21, 2021 12/21/2021

Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721

SEE ALL NEWS AND RELEASES >